{
    "clinical_study": {
        "@rank": "90650", 
        "acronym": "HyStOON", 
        "arm_group": [
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20"
            }, 
            {
                "arm_group_label": "hydrocortison", 
                "arm_group_type": "Active Comparator", 
                "description": "50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24"
            }
        ], 
        "brief_summary": {
            "textblock": "The main objectives of the study are 1)to examine the immediate (2 hours) and delayed (8\n      hours) effects of intravenous hydrocortison on macro and microvascular post-ischemic\n      vasoreactivity, in septic shock adult patients; 2) to examine possible correlations between\n      post-ischemic flow-mediated dilation (FMD) of the brachial artery (assessed by ultrasound\n      imaging) and post-ischemic recovery slope of the thenar oxygen saturation (StO2) (assessed\n      by near-infrared spectroscopy)."
        }, 
        "brief_title": "Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Septic Shock", 
            "Adult"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Shock", 
                "Shock, Septic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Two primary end points, considered as reflecting vasoreactivity will be assessed :\n\n        1. Flow-mediated dilation (FMD) of the brachial artery, measured by ultrasound imaging,\n           expressed in mm or in percentage, will be calculated from artery diameters measured\n           before and after a vascular occlusion test (cuff around arm or forearm).\n\n        2. recovery slope of thenar oxygen saturation (StO2), assessed by near infrared\n           spectroscopy (NIRS), expressed in %/second, will be recorded after the vascular\n           occlusion test.\n\n      The two primary end points (FMD and recovery slope of StO2)will be assessed at the following\n      timepoints :\n\n        -  baseline (before first injection of placebo or hydrocortison)\n\n        -  2 hours after first injection of placebo or hydrocortison\n\n        -  2 hours after second injection of placebo or hydrocortison (i.e. 8 hours after first\n           injection)\n\n        -  4 to 6 hours after third injection\n\n        -  4 to 6 hours after fourth injection (optional)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age over 18 yrs\n\n          -  consent obtained\n\n          -  septic shock (according to international definition)\n\n          -  patient sedated and submitted to invasive mechanical ventilation\n\n          -  no need for surgery expected within 24 hours after enrollment\n\n          -  patient has received at least one dose of large spectrum antibiotics\n\n          -  superior vena cava catheter in place\n\n          -  patient carrying a thermodilution device for cardiac output measurement\n\n          -  stable mean arterial pressure within 65-5 mmHg limits for at least 2 hours;\n\n        Exclusion Criteria:\n\n          -  pregnancy\n\n          -  age below 18 years\n\n          -  patient treated with iv continuous epinephrine\n\n          -  chronic occlusive arteriopathy of the upper limbs\n\n          -  regular or recent treatment with glibenclamide or glipizide\n\n          -  regular or recent treatment with steroids\n\n          -  known surrenal insufficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01817153", 
            "org_study_id": "CHRO-2012-04", 
            "secondary_id": "2012-004736-39"
        }, 
        "intervention": [
            {
                "arm_group_label": "hydrocortison", 
                "intervention_name": "hydrocortison hemisuccinate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo followed by hydrocortisone hemisuccinate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cortisol succinate", 
                "Hydrocortisone acetate", 
                "Hydrocortisone 17-butyrate 21-propionate", 
                "Hydrocortisone", 
                "Hydrocortisone-17-butyrate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 17, 2013", 
        "location": {
            "contact": {
                "last_name": "Thierry Boulain, MD"
            }, 
            "contact_backup": {
                "last_name": "Johann Le Drogoff"
            }, 
            "facility": {
                "address": {
                    "city": "Orl\u00e9ans", 
                    "country": "France", 
                    "zip": "45000"
                }, 
                "name": "Centre Hospitalier R\u00e9gional d'Orl\u00e9ans"
            }, 
            "investigator": {
                "last_name": "Thierry Boulain, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Intravenous Hydrocortison on Post-ischemic Brachial Artery Dilation and on Thenar Oxygen Saturation in Adult Septic Shock. A Human Placebo-controlled Randomized Study.", 
        "overall_contact": {
            "email": "thierry.boulain@chr-orleans.fr", 
            "last_name": "Thierry Boulain, MD"
        }, 
        "overall_contact_backup": {
            "email": "johann.le-drogoff@chr-orleans.fr", 
            "last_name": "Johann Le Drogoff"
        }, 
        "overall_official": {
            "affiliation": "Centre Hospitalier R\u00e9gional d'Orl\u00e9ans, France", 
            "last_name": "Thierry Boulain, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Vasoreactivity", 
            "safety_issue": "No", 
            "time_frame": "every 6 hours over the first 24 hours of intervention"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01817153"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centre Hospitalier R\u00e9gional d'Orl\u00e9ans", 
            "investigator_full_name": "Thierry BOULAIN", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Centre Hospitalier R\u00e9gional d'Orl\u00e9ans", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier R\u00e9gional d'Orl\u00e9ans", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}